Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease
The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the α-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.
1. A messenger RNA (mRNA) comprising:
an open reading frame (ORF) encoding a human α-galactosidase A (GLA) polypeptide of SEQ ID NO: 1, wherein the ORF comprises a nucleotide sequence 95% identical to the nucleotide sequence of SEQ ID NO: 79.
2. An mRNA comprising an ORF encoding a human GLA polypeptide of SEQ ID NO: 1, wherein the ORF comprises a nucleotide sequence 96% identical to the nucleotide sequence of SEQ ID NO: 79.
3. An mRNA comprising an ORF encoding a human GLA polypeptide of SEQ ID NO: 1, wherein the ORF comprises a nucleotide sequence 97% identical to the nucleotide sequence of SEQ ID NO: 79.
4. An mRNA comprising an ORF encoding a human GLA polypeptide of SEQ ID NO: 1, wherein the ORF comprises a nucleotide sequence 100% identical to the nucleotide sequence of SEQ ID NO: 79.
5. The mRNA of claim 1 , wherein the mRNA comprises a 5′ terminal cap comprising a guanine cap nucleotide containing an N7 methylation and the 5′-terminal nucleotide of the mRNA contains a 2′-O-methyl.
6. The mRNA of claim 1 , wherein the mRNA comprises a poly-A tail about 100 residues in length.
7. The mRNA of claim 1 , wherein at least 95% of uridines in the ORF are 5-methoxyuridines.
8. The mRNA of claim 1 , wherein at least 99% of uridines in the ORF are 5-methoxyuridines.
9. The mRNA of claim 1 , wherein 100% of uridines in the ORF are 5-methoxyuridines.
10. The mRNA of claim 4 , wherein the mRNA comprises a 5′ terminal cap comprising a guanine cap nucleotide containing an N7 methylation and the 5′-terminal nucleotide of the mRNA contains a 2′-O-methyl.
11. The mRNA of claim 4 , wherein the mRNA comprises a poly-A tail about 100 residues in length.
12. The mRNA of claim 4 , wherein at least 95% of uridines in the ORF are 5-methoxyuridines.
13. The mRNA of claim 4 , wherein at least 99% of uridines in the ORF are 5-methoxyuridines.
14. The mRNA of claim 4 , wherein 100% of uridines in the ORF are 5-methoxyuridines.
15. A lipid nanoparticle comprising the mRNA of claim 1 .
16. A lipid nanoparticle comprising the mRNA of claim 4 .
17. A lipid nanoparticle comprising the mRNA of claim 2 .
18. A lipid nanoparticle comprising the mRNA of claim 3 .
19. A lipid nanoparticle comprising the mRNA of claim 9 .
20. A lipid nanoparticle comprising the mRNA of claim 14 .
21. The mRNA of claim 2 , wherein 100% of uridines in the ORF are 5-methoxyuridines.
22. The mRNA of claim 3 , wherein 100% of uridines in the ORF are 5-methoxyuridines.
23. A lipid nanoparticle comprising the mRNA of claim 21 .
24. A lipid nanoparticle comprising the mRNA of claim 22 .
25. A pharmaceutical composition comprising the mRNA of claim 1 and a pharmaceutically acceptable excipient.
26. A pharmaceutical composition comprising the mRNA of claim 2 and a pharmaceutically acceptable excipient.
27. A pharmaceutical composition comprising the mRNA of claim 3 and a pharmaceutically acceptable excipient.
28. A pharmaceutical composition comprising the mRNA of claim 4 and a pharmaceutically acceptable excipient.
29. A pharmaceutical composition comprising the lipid nanoparticle of claim 20 and a pharmaceutically acceptable excipient.